HUP0203688A2 - N-formil-peptid receptor G-protein-kináz szignálreakcióútmódosító hatóanyaggal képzett komplexe - Google Patents

N-formil-peptid receptor G-protein-kináz szignálreakcióútmódosító hatóanyaggal képzett komplexe

Info

Publication number
HUP0203688A2
HUP0203688A2 HU0203688A HUP0203688A HUP0203688A2 HU P0203688 A2 HUP0203688 A2 HU P0203688A2 HU 0203688 A HU0203688 A HU 0203688A HU P0203688 A HUP0203688 A HU P0203688A HU P0203688 A2 HUP0203688 A2 HU P0203688A2
Authority
HU
Hungary
Prior art keywords
protein kinase
pro
receptor complex
modification agent
signal pathway
Prior art date
Application number
HU0203688A
Other languages
English (en)
Hungarian (hu)
Inventor
James A. Clagett
Craig Palmer
Original Assignee
Histatek, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Histatek, Llc filed Critical Histatek, Llc
Publication of HUP0203688A2 publication Critical patent/HUP0203688A2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
HU0203688A 1999-10-15 2000-10-12 N-formil-peptid receptor G-protein-kináz szignálreakcióútmódosító hatóanyaggal képzett komplexe HUP0203688A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15967799P 1999-10-15 1999-10-15
PCT/US2000/028183 WO2001029069A1 (en) 1999-10-15 2000-10-12 N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agent

Publications (1)

Publication Number Publication Date
HUP0203688A2 true HUP0203688A2 (hu) 2003-02-28

Family

ID=22573520

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203688A HUP0203688A2 (hu) 1999-10-15 2000-10-12 N-formil-peptid receptor G-protein-kináz szignálreakcióútmódosító hatóanyaggal képzett komplexe

Country Status (16)

Country Link
EP (1) EP1222199A4 (de)
JP (1) JP2004507441A (de)
KR (1) KR20020057972A (de)
CN (1) CN100497374C (de)
AU (1) AU8014200A (de)
BR (1) BR0014742A (de)
CA (1) CA2387559A1 (de)
CZ (1) CZ20021342A3 (de)
EA (1) EA200200451A1 (de)
HU (1) HUP0203688A2 (de)
IL (1) IL149125A0 (de)
MX (1) MXPA02003782A (de)
NO (1) NO20021732L (de)
PL (1) PL356096A1 (de)
WO (1) WO2001029069A1 (de)
ZA (1) ZA200202937B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1138692A1 (de) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragmente des menschlichen Choriongonadotropins als Immunoregulatoren
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1300418A1 (de) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Genregulation durch Oligopeptide
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
WO2004100978A1 (en) * 2003-05-13 2004-11-25 Medvet Science Pty. Ltd. A method of modulating cellular transmigration and agents for use therein
WO2007004869A2 (en) 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
EP1864692A1 (de) 2006-06-07 2007-12-12 Biotempt B.V. Verwendung von peptiden zum Schutz von Strahlenschäden
US20110082091A1 (en) * 2009-09-28 2011-04-07 Theramab Gmbh Method for Preclinical Testing of Immunomodulatory Drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69840851D1 (de) * 1997-11-13 2009-07-09 Mowycal Lending Llc Kleine peptide und methoden zur behandlung von asthma und entzündungen

Also Published As

Publication number Publication date
EA200200451A1 (ru) 2002-10-31
PL356096A1 (en) 2004-06-14
NO20021732L (no) 2002-06-12
JP2004507441A (ja) 2004-03-11
NO20021732D0 (no) 2002-04-12
BR0014742A (pt) 2002-08-27
MXPA02003782A (es) 2002-12-13
WO2001029069A1 (en) 2001-04-26
CA2387559A1 (en) 2001-04-26
ZA200202937B (en) 2003-09-23
IL149125A0 (en) 2002-11-10
CN100497374C (zh) 2009-06-10
EP1222199A1 (de) 2002-07-17
EP1222199A4 (de) 2003-03-12
CN1633447A (zh) 2005-06-29
KR20020057972A (ko) 2002-07-12
AU8014200A (en) 2001-04-30
CZ20021342A3 (cs) 2003-01-15

Similar Documents

Publication Publication Date Title
HUP0203688A2 (hu) N-formil-peptid receptor G-protein-kináz szignálreakcióútmódosító hatóanyaggal képzett komplexe
Roy et al. Chronic morphine treatment differentiates T helper cells to Th2 effector cells by modulating transcription factors GATA 3 and T-bet
Horvath Endomorphin-1 and endomorphin-2: pharmacology of the selective endogenous μ-opioid receptor agonists
TR200000913T2 (tr) Tıbbi maddeler
Di Prisco et al. RANTES‐mediated control of excitatory amino acid release in mouse spinal cord
AU2003213768A8 (en) Use of benzimidazole analogs in the treatment of cell proliferation
ID22216A (id) Penggunaan antagonis-antagonis reseptor kanabinoid pusat untuk mengatur selera makan
WO2003103697A3 (en) USE OF COMPOUNDS HAVING GIP ACTIVITY IN THE TREATMENT OF DISORDERS ASSOCIATED WITH ABNORMAL CELL LOSS AND / OR IN THE TREATMENT OF OBESITY
MXPA03009185A (es) Antagonistas de receptor a2a de adenosina combinados con compuestos de actividad neurotrofica en el tratamiento de la enfermedad de parkinson.
Tang et al. Trifluoperazine, an orally available clinically used drug, disrupts opioid antinociceptive tolerance
WO2005000240A3 (en) Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
ATE356994T1 (de) Screeningverfahren mit pim1-kinase oder pim3- kinase
Lissandron et al. Compartmentalized cAMP/PKA signalling regulates cardiac excitation–contraction coupling
ATE303439T1 (de) Intrazelluläre isoform von interleukin-1 rezeptor antagonist
IL206566A0 (en) Use of an antagonist to the igs4 neuromedin receptor polypeptide for the preparation of a medicament for the treatment of a disease related to the expression or acitivity of the igs4 neuromedin receptor polypeptide
WO2003106681A3 (de) Antisense oligonukleotide gegen pim1
AU4856600A (en) Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder
ATE400275T1 (de) Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus
Narita et al. Up-regulation of spinal μ-opioid receptor function to activate G-protein by chronic naloxone treatment
NO20001894D0 (no) Anvendelse av TNF-antagonister som medikamenter for behandling av septiske sykdommer
WO2001042287A3 (en) Putative human g-protein coupled receptors
INOUE et al. Mechanisms of action of eperisone on isolated dog saphenous arteries and veins
Murphy et al. Pertussis toxin differentiates between α1-and α2-adrenoceptor-mediated inhibition of noradrenaline release from rat kidney cortex
Dooper et al. Potentiation of adenylyl cyclase in human peripheral blood mononuclear cells by cell-activating stimuli
COSTA et al. Assessment of δ‐opioid receptor activation by a series of peptides in cultured cells